Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 8 (4) |
| Completed vs Stopped Early | 8 / 4 (18.2%) |
| Median Closed Actual Enrollment | 146 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Barts Health NHS Trust | London | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04695080 | ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis | Phase II/III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Queen Mary University of London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.